Updates are available Correction dated 2023-04-15
Click to view Correction: https://doi.org/10.1007/s11239-023-02809-7
-
Authors
Limperger, Verena http://orcid.org/0000-0003-4138-0161
Kenet, Gili
Kiesau, Bettina
Köther, Max
Schmeiser, Malin
Langer, Florian
Juhl, David
Shneyder, Maria
Franke, Andre
Klostermeier, Ulrich K.
Mesters, Rolf
Rühle, Frank
Stoll, Monika
Steppat, Dagmar
Kowalski, Dorothee
Rocke, Angela
Kuta, Piotr
Bajorat, Tido
Torge, Antje
Neuner, Bruno
Junker, Ralf
Nowak-Göttl, Ulrike
-
Funding
Funding for this research was provided by:
Förderverein “Schlaganfall und Thrombosen im Kindesalter e.V.”
Interdisziplinäres Zentrum für Klinische Forschung (IZKF: CRA01-09)
Gesellschaft für Thrombose und Hämostaseforschung/ Society of Thrombosis and Hemostasis Research“ (GTH 2016)
- License Information
-
More Information
Article History
First Online: 27 June 2020
Change Date: 15 April 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s11239-023-02809-7
Compliance with ethical standards
:
: Verena Limperger: personal fees from Bristol-Myers Squibb, Amedes holding GmbH, CSL Behring, NovoNordisk, non-financial support from Octapharma, NovoNordisk, outside the submitted work. Gili Kenet: personal fees from Bayer, personal fees from Boehringer Ingelheim, personal fees from Daiichi Sankyo, other from Pfizer, outside the submitted work. Bettina Kiesau: personal fees and other from Sobi, outside the submitted work. Max Köther, Malin Schmeiser, David Juhl, Andre Franke, Ulrich K. Klostermeier, Rolf Mesters, Frank Rühle, Monika Stoll, Dagmar Steppat, Antje Torge, Bruno Neuner, and Ralf Junker declared that they have no conflict of interest. Florian Langer: personal fees from Bayer, personal fees from Bristol-Myers Squibb, personal fees from Daiichi Sankyo, personal fees from LEO Pharma, grants and personal fees from Pfizer, personal fees from Chugai, personal fees from Roche, personal fees from SOBI, personal fees from Takeda, personal fees from CSL Behring, personal fees from SOBI, personal fees from Werfen, personal fees from Siemens, personal fees from Grifols, personal fees from Novo Nordisk, personal fees from Octapharma, personal fees from Ablynx, outside the submitted work. Maria Shneyder: personal fees from NovoNordisk, Octapharma and Takeda, outside the submitted work. Dorothee Kowalski: non-financial support from Octapharma, NovoNordisk and LFB GmbH outside the submitted work. Angela Rocke: personal fees from Octapharm, CSL Behring outside the submitted work. Piotr Kuta: personal fees from CSL Behring, NovoNordisk, Octapharma, Stago, Aspen outside the submitted work. Tido Bajorat: personal fees from BFSH e.V. (Bündnis zur Förderung der Sicherheit von Hämophilen), personal fees from Octapharma, outside the submitted work. Ulrike Nowak-Göttl: grants from Octapharma, grants from LFB, other from Bayer Vital, other from Boehringer-Ingelheim, outside the submitted work.
